Abstract
Over the past 3 years, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread through human populations in several waves, resulting in a global health crisis. In response, genomic surveillance efforts have proliferated in the hopes of tracking and anticipating the evolution of this virus, resulting in millions of patient isolates now being available in public databases. Yet, while there is a tremendous focus on identifying newly emerging adaptive viral variants, this quantification is far from trivial. Specifically, multiple co-occurring and interacting evolutionary processes are constantly in operation and must be jointly considered and modeled in order to perform accurate inference. We here outline critical individual components of such an evolutionary baseline model-mutation rates, recombination rates, the distribution of fitness effects, infection dynamics, and compartmentalization-and describe the current state of knowledge pertaining to the related parameters of each in SARS-CoV-2. We close with a series of recommendations for future clinical sampling, model construction, and statistical analysis.
| Original language | English |
|---|---|
| Article number | e1011265 |
| Pages (from-to) | e1011265 |
| Journal | PLoS Pathogens |
| Volume | 19 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2023 |
Funding
Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health (NIH) under Award Numbers P20GM102546 and P30GM140963. NIH awards R35GM124701 (BSC) and R35GM139383 (JDJ) also supported this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We would like to thank Jeremy Kamil and Timothy Kowalik for helpful comments on the manuscript, and Will Conner, David Xing, and the University of Montana Genomics Core for data contributions.
| Funder number |
|---|
| R35GM139383, R35GM124701, P20GM102546, P30GM140963 |
Keywords
- Humans
- SARS-CoV-2
- COVID-19
- Genomics